How is the Candida score calculated and what antifungal therapy is recommended based on the score?

Candida Score Calculation and Antifungal Therapy Recommendations

The Candida score is calculated by assigning points to four clinical variables: total parenteral nutrition (1 point), surgery (1 point), multifocal Candida colonization (1 point), and severe sepsis (2 points), with a score ≥3 indicating high risk for invasive candidiasis and warranting empiric antifungal therapy with an echinocandin as first-line treatment.

How to Calculate the Candida Score

The Candida score uses a simple additive system based on four risk factors 1, 2:

• Total parenteral nutrition: +1 point
• Surgery: +1 point
• Multifocal Candida colonization: +1 point (defined as Candida growth from ≥2 non-contiguous body sites)
• Severe sepsis: +2 points

Total possible score range: 0-5 points

Clinical Interpretation

• Score <3: Invasive candidiasis is highly improbable (rate <5%), empiric antifungal therapy generally not indicated 2, 3
• Score ≥3: High risk for invasive candidiasis, empiric antifungal therapy should be initiated 1, 2, 3
• Score ≥4: Very high risk (17.6% with score 4,50% with score 5) 3

The score demonstrates strong discriminatory power with sensitivity of 81% and specificity of 74% at a cutoff of 2.5 1. Multiple validation studies confirm that patients with scores <3 have invasive candidiasis rates consistently below 5% 2, 3.

Antifungal Therapy Based on Candida Score

For Patients with Score ≥3 (High Risk)

First-line empiric therapy: Echinocandin 4, 5

• Caspofungin: 70 mg loading dose, then 50 mg daily
• Micafungin: 100 mg daily
• Anidulafungin: 200 mg loading dose, then 100 mg daily

This recommendation is particularly critical for patients with septic shock, where echinocandins demonstrate superiority over fluconazole 4, 5.

Alternative Regimens

Fluconazole (acceptable alternative if specific criteria met) 5:

• Dose: 800 mg (12 mg/kg) loading dose, then 400 mg (6 mg/kg) daily
• Use only when:
  • No recent azole exposure
  • Not colonized with azole-resistant Candida species
  • Local epidemiology does not show azole resistance

Lipid formulation amphotericin B: 3-5 mg/kg daily 5

• Reserved for intolerance to other agents

Duration of Therapy

• Empiric therapy duration: 2 weeks for patients who improve 5
• Reassessment at 4-5 days: If no clinical response and no evidence of invasive candidiasis develops, consider stopping antifungal therapy 5

Important Clinical Considerations

When NOT to Treat (Score <3)

The most recent guidelines emphasize against broad implementation of fever-driven treatment strategies 4. Do not initiate empiric antifungals in ICU patients with fever as the sole symptom and a Candida score <3, as invasive candidiasis is highly improbable in this population 2, 3.

Special Circumstances Requiring Treatment Despite Lower Scores

Initiate empiric antifungal therapy even with lower scores if 4, 5:

• Septic shock is present
• Deteriorating clinical status with additional risk factors (prolonged ICU stay, indwelling vascular catheter)

Common Pitfalls to Avoid

1. Central venous catheters alone are NOT part of the score - they were not significant independent predictors in the original derivation study 1

2. Colonization index vs. Candida score - The Candida score (area under ROC curve 0.774) outperforms the colonization index (0.633) for predicting invasive candidiasis 2

3. Don't delay treatment in high-risk patients - The relative risk for developing invasive candidiasis in colonized patients without antifungal treatment is 6.83 2

4. Local epidemiology matters - If your institution has high rates of azole-resistant species (particularly C. auris or azole-resistant C. parapsilosis), echinocandins should be strongly preferred even for lower-risk scenarios 4, 6

Adjunctive Measures

Regardless of Candida score, always ensure 4, 5:

• Source control: Remove central venous catheters within 48-72 hours if present
• Infectious disease consultation: Strongly recommended for all patients with candidemia or invasive candidiasis
• Daily blood cultures: Continue until three consecutive negative days

Monitoring Response

For patients started on empiric therapy with score ≥3, the 2025 global guidelines emphasize earlier IV-to-oral step-down in stable non-neutropenic patients once susceptibility results are available and clinical improvement is documented 4, 6.